Pioglitazone the treatment of schizophrenia
Phase 2
- Conditions
- schizophrenia.schizophrenia
- Registration Number
- IRCT201110281556N30
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Inclusion Criteria: age between 18-50 years old; diagnosis of Schizophrenia based on DSM IV; chronic Schizophrenia( duration of the disorder>2 years); minimum Score of 60 on Positive and Negative Scale; being treated with a stable dose of risperidone for at least 8 weeks and clinically stable for at least 4 weeks prior to entry.
Exclusion Criteria
substance dependence; IQ <70; any other mental disorder on axis I; any serious medical or neurological problem; receiving ECT during the last 14 days and hepatic or renal diseases.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of schizophrenia. Timepoint: Baseline and weeks 2-4-6-8 after beginig of treatment. Method of measurement: Positive and Negative Syndrome Scale (PANSS).
- Secondary Outcome Measures
Name Time Method